Monday, November 11, 2024

PhRMA shells out to get PBM reform over finish line

Presented by the Small Business Payments Alliance: Delivered daily, Influence gives you a comprehensive rundown and analysis of all lobby hires and news on K Street.
Nov 11, 2024 View in browser
 
POLITICO Influence Newsletter Header

By Caitlin Oprysko

Presented by 

the Small Business Payments Alliance

With help from Daniel Lippman

WELCOME BACK: Drugmakers’ top lobbying group is welcoming lawmakers back to town this week with a seven-figure ad blitz, ramping up pressure on Congress to enact a crackdown on pharmaceutical middlemen as part of its final year-end sprint.

— The new ad buy from PhRMA features the recurring “Middleman” character representing pharmaceutical benefit managers, and argues that “Congress should make sure savings” from drug rebate programs “go directly to patients, not middlemen.” The campaign will run in news outlets and digital and social media nationwide, with a particular focus within the Beltway.

— The lame-duck session that kicks off tomorrow is one of lawmakers’ final shots to capitalize on a burst of increasingly rare bipartisan momentum for reining in PBMs, which drugmakers have sought to paint as the real culprit behind high drug prices. The drug lobby isn’t the only one targeting PBMs in Washington, however — independent and chain pharmacies as well as manufacturers have all poured hundreds of thousands of dollars into ad campaigns pillorying drug middlemen.

— The House and key Senate committees have both passed bills that aim to curtail PBM practices like spread pricing or enacting new transparency requirements — reforms that the PBM industry has fiercely lobbied against.

— PBMs’ main trade group, the Pharmaceutical Care Management Association , has shelled out to defend the industry in Washington. The group spent a record $15.4 million on lobbying last year (up from $8.7 million the year before) and is on track to surpass that total through the first three quarters of 2024.

— It’s unclear whether lawmakers will be able to coalesce around one PBM proposal even if a broader health care package does materialize in the lame duck. But Eugenia Pierson, a health lobbyist at Arnold & Porter Kaye Scholer , suggested last week that that might be an easier hurdle to overcome than starting all over again with a new Congress. PBM reform is one of a handful of issues that would “arguably be more helpful to move in this environment than have to tackle again in a new political landscape next Congress,” she told PI.

Happy Monday and welcome to PI. What are you hearing from clients about the new administration, the lame duck or the next Congress? My inbox is open: coprysko@politico.com . And be sure to follow me on X: @caitlinoprysko.

 

A message from the Small Business Payments Alliance:

Small business owners have a message for Congress: don’t jeopardize our secure and convenient payments system so corporate mega-stores can pad their profits. Businesses around the country rely on credit cards to provide safe, secure payment processing for customers. The Durbin-Marshall credit card bill threatens security, creating a “routing mandate” requiring cards to run on untested networks, potentially leading to fraud. Listen to the voices of real small business owners - oppose the Durbin-Marshall bill.

 

PALESTINIANS LOOK FOR INROADS WITH TRUMP: As the U.S. prepares to inaugurate Donald Trump for the second time, The New York Times’ Adam Rasgon and Charles Homans report that Palestinian leader Mahmoud Abbas has embarked on an expansive campaign “to rehabilitate his once adversarial relationship with Mr. Trump as Palestinians reckon with an incoming president who expressed near unreserved backing for Israel in his first term.”

— “As president, Mr. Trump advanced policies that infuriated the Palestinian Authority, which has limited autonomy over parts of the West Bank under Israeli occupation. … Incensed, Mr. Abbas barred senior Palestinian officials from contact with people in the Trump administration. But Mr. Trump has publicly called for the war in Gaza to stop. Mr. Abbas appears to be reversing course, hoping to influence the president-elect’s views on the conflict and cease-fire talks.”

LEFTY GROUPS GIRD FOR BATTLE: “Some of the largest donors to Kamala Harris and to progressive causes worry they could face investigations and retaliation from the Trump Administration next year — and are preparing for the possibility,” Semafor’s Ben Smith and Shelby Talcott report.

— “At least one of the groups receiving LinkedIn Co-founder Reid Hoffman’s vast contributions has consulted lawyers about the possibility of an investigation, a person close to the group said. And leaders of progressive nonprofit organizations were brought together Thursday at the East 62nd Street mansion that houses the Andrew W. Mellon Foundation by that group’s leader, Elizabeth Alexander, and the president of the JPB Foundation, Deepak Bhargava.”

— “Progressive leaders are split on the seriousness of the short-term legal threat. Some are skeptical that Trump would use the federal apparatus to attack Democratic donors and progressive nonprofits that veer toward electoral politics — in part because a move like that would also alarm Republican donors and non-profits. Others are closer to outright panic.”

RELATED READ: “Congress is about to gift Trump sweeping powers to crush his political enemies,” by The Intercept’s Noah Hurowitz

ANNALS OF CAMPAIGN FINANCE: The Daily Beast revised a previous report on the amount of money that the Trump campaign and pro-Trump PACs directed to campaign co-manager Chris LaCivita over the past two years.

— Though the Beast’s Michael Isikoff initially reported LaCivita had personally received $22 million from the campaign, on Friday the outlet revised that number down to $19.2 million and noted that the story “has also been updated to make clear that payments were to LaCivita’s LLC not to LaCivita personally.”

GSK DROPS BIO: “Pharmaceutical industry giant GSK plans to depart the biotechnology industry’s largest trade group, the Biotechnology Innovation Organization,” with a spokesperson telling Stat News’ John Wilkerson, Lizzy Lawrence, Rachel Cohrs Zhang and Sarah Owermohle that the company opted not to renew is membership during its annual evaluation.

— “‘At this time, we believe there are other areas we can focus our resources,’ the spokesperson said. The company is maintaining its membership in the brand drug lobby PhRMA, and in state-based BIO affiliates, the spokesperson said.”

— “GSK is the fifth biopharmaceutical company to depart BIO in roughly a year, including major pharmaceutical companies Pfizer and UCB. Those departures coincided with a drop in lobbying spending from the group and other challenges. The lobby laid off 30 employees, including several senior leaders, in a restructuring earlier this year. The lobby has had four CEOs over the past four years.”

KNOWING HOWARD LUTNICK: “The financier Howard Lutnick has been given a high-profile assignment from President-elect Donald J. Trump, one that raises questions about the Wall Street executive’s dual role and what he might gain from it,” the Times’ Kate Kelly and Ken Vogel report.

— “As co-chair of the transition team, Mr. Lutnick is in charge of identifying 4,000 new hires to fill the second Trump administration, including antitrust officials, securities lawyers and national security advisers who have global expertise.”

— “But Mr. Lutnick has not stepped away from running financial firms that serve corporate clients, traders, cryptocurrency platforms and real estate ventures around the world — all of which are regulated by the same agencies whose appointees he is helping to find.”

— “Given his sprawling business interests, it’s not known how Mr. Lutnick might keep from violating the transition’s own code of ethics,” which “say that individuals who work on the team must disqualify themselves from matters that may directly conflict with their own financial interests or those of an organization with which they do business.”

Jobs report

None.

 

A message from the Small Business Payments Alliance:

Advertisement Image

 
New Joint Fundraisers

None.

New PACs

Conservative Voters Coalition (Super PAC)

Jonathan Jenkins (Super PAC)

New Lobbying REGISTRATIONS

Commonwealth Research Associates, LLC: Jones Fortuna Lp On Behalf Of Southwest Missouri Water

The Jackson Group, LLC: Skylark Services, LLC

Venture Government Strategies, LLC (Fka Hobart Hallaway & Quayle Ventures, LLC): Sbir Advisors Obo Appgate Cybersecurity Inc

Venture Government Strategies, LLC (Fka Hobart Hallaway & Quayle Ventures, LLC): Sbir Advisors Obo Circle Optics Inc

New Lobbying Terminations

Government Relations Group, LLC: Tenant Evaluation LLC

Hicks-Ray Associates: Gulf Coast Water Authority

Leroy Jones, Jr.: Kbk Consulting Group Obo National Collegiate Athletic Association (Ncaa)

Ocal Lobbying Group: Almisa, Almidones Sociedad Anonima S.A.

Ocal Lobbying Group: Anshau Agrograndera

Riverside Strategic Solutions, LLC: City Of Gardner, Ks

Rulon & White Governance Strategies: Arizona Business And Information Technology Coalition

Rulon & White Governance Strategies: Mxsquared, LLC

Saunders Global Diplomacy: Myland

The Petrizzo Group, Inc.: Dialysis Patient Citizens

 

A message from the Small Business Payments Alliance:

We are small businesses asking Congress to oppose the Durbin-Marshall credit card bill. Why? Our businesses earn more when customers use credit cards – they spend more, and we save without the added hassle and expense of counting and securing cash. We also use credit cards for monthly expenses and invest card rewards back into our business. The Durbin-Marshall bill puts credit cards and their benefits at risk. Please don’t add one more challenge to our plate. Oppose Durbin-Marshall.

 
 

Follow us

Follow us on Facebook Follow us on Twitter Follow us on Instagram Listen on Apple Podcast
 

To change your alert settings, please log in at https://login.politico.com/?redirect=https%3A%2F%2Fwww.politico.com/settings

This email was sent to edwardlorilla1986.paxforex@blogger.com by: POLITICO, LLC 1000 Wilson Blvd. Arlington, VA, 22209, USA

Unsubscribe | Privacy Policy | Terms of Service

No comments:

Post a Comment

Can You Really Turn $10k Into $137k?

...